Stem definition | Drug id | CAS RN |
---|---|---|
human origin | 5316 | 1578199-75-3 |
Molecule | Description |
---|---|
Synonyms:
|
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.
|
Dose | Unit | Route |
---|---|---|
4 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 27, 2018 | FDA | ELI LILLY AND CO | |
Jan. 22, 2021 | PMDA | Eli Lilly Japan K.K. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Underdose | 804.34 | 28.63 | 228 | 5644 | 27228 | 63455922 |
Injection site pain | 626.48 | 28.63 | 282 | 5590 | 129518 | 63353632 |
Accidental underdose | 342.05 | 28.63 | 60 | 5812 | 743 | 63482407 |
Injection site erythema | 332.22 | 28.63 | 159 | 5713 | 83015 | 63400135 |
Injection site reaction | 283.60 | 28.63 | 128 | 5744 | 58396 | 63424754 |
Injection site pruritus | 278.30 | 28.63 | 117 | 5755 | 44999 | 63438151 |
Injection site urticaria | 226.75 | 28.63 | 74 | 5798 | 13999 | 63469151 |
Injection site swelling | 214.41 | 28.63 | 99 | 5773 | 47473 | 63435677 |
Migraine | 196.77 | 28.63 | 121 | 5751 | 103225 | 63379925 |
Therapeutic response shortened | 138.35 | 28.63 | 49 | 5823 | 11839 | 63471311 |
Injection site rash | 136.93 | 28.63 | 55 | 5817 | 18754 | 63464396 |
Injection site mass | 110.22 | 28.63 | 47 | 5825 | 18609 | 63464541 |
Incorrect dose administered | 103.31 | 28.63 | 66 | 5806 | 59902 | 63423248 |
Product dose omission issue | 99.35 | 28.63 | 115 | 5757 | 234198 | 63248952 |
Injection site haemorrhage | 92.24 | 28.63 | 45 | 5827 | 24269 | 63458881 |
Headache | 80.80 | 28.63 | 179 | 5693 | 633062 | 62850088 |
Constipation | 70.55 | 28.63 | 95 | 5777 | 224848 | 63258302 |
Weight increased | 55.68 | 28.63 | 92 | 5780 | 260700 | 63222450 |
Urticaria | 54.96 | 28.63 | 72 | 5800 | 165730 | 63317420 |
Injection site warmth | 54.26 | 28.63 | 27 | 5845 | 15168 | 63467982 |
Alopecia | 44.56 | 28.63 | 97 | 5775 | 337439 | 63145711 |
Injection site bruising | 41.62 | 28.63 | 33 | 5839 | 41877 | 63441273 |
Incorrect product formulation administered | 37.02 | 28.63 | 7 | 5865 | 134 | 63483016 |
Product storage error | 29.59 | 28.63 | 18 | 5854 | 14938 | 63468212 |
Device difficult to use | 29.51 | 28.63 | 17 | 5855 | 12779 | 63470371 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Underdose | 190.55 | 54.95 | 44 | 521 | 13736 | 34942630 |
Injection site pain | 71.92 | 54.95 | 26 | 539 | 38979 | 34917387 |
Injection site erythema | 67.70 | 54.95 | 20 | 545 | 15879 | 34940487 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Underdose | 237.47 | 32.74 | 77 | 3134 | 33074 | 79708103 |
Injection site pain | 207.74 | 32.74 | 102 | 3109 | 129736 | 79611441 |
Injection site erythema | 202.66 | 32.74 | 86 | 3125 | 78111 | 79663066 |
Injection site pruritus | 174.08 | 32.74 | 65 | 3146 | 42218 | 79698959 |
Migraine | 137.47 | 32.74 | 68 | 3143 | 87425 | 79653752 |
Accidental underdose | 126.53 | 32.74 | 23 | 3188 | 839 | 79740338 |
Injection site reaction | 118.10 | 32.74 | 53 | 3158 | 54732 | 79686445 |
Injection site urticaria | 100.72 | 32.74 | 32 | 3179 | 12794 | 79728383 |
Injection site swelling | 99.66 | 32.74 | 45 | 3166 | 47087 | 79694090 |
Injection site rash | 67.97 | 32.74 | 26 | 3185 | 17928 | 79723249 |
Injection site mass | 61.56 | 32.74 | 25 | 3186 | 20159 | 79721018 |
Headache | 52.69 | 32.74 | 94 | 3117 | 653678 | 79087499 |
Device difficult to use | 42.25 | 32.74 | 17 | 3194 | 13368 | 79727809 |
Product dose omission issue | 40.85 | 32.74 | 50 | 3161 | 247487 | 79493690 |
Alopecia | 40.25 | 32.74 | 48 | 3163 | 231307 | 79509870 |
Wrong technique in product usage process | 40.12 | 32.74 | 29 | 3182 | 73846 | 79667331 |
Incorrect dose administered | 39.17 | 32.74 | 29 | 3182 | 76601 | 79664576 |
Injection site haemorrhage | 38.79 | 32.74 | 20 | 3191 | 27850 | 79713327 |
Injection site warmth | 34.01 | 32.74 | 15 | 3196 | 14792 | 79726385 |
Urticaria | 33.13 | 32.74 | 39 | 3172 | 185162 | 79556015 |
None
Source | Code | Description |
---|---|---|
ATC | N02CD02 | NERVOUS SYSTEM ANALGESICS ANTIMIGRAINE PREPARATIONS Calcitonin gene-related peptide (CGRP) antagonists |
MeSH PA | D000700 | Analgesics |
MeSH PA | D000077221 | Calcitonin Gene-Related Peptide Receptor Antagonists |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Migraine | indication | 37796009 | DOID:6364 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Calcitonin gene-related peptide 1 | GPCR | ANTIBODY BINDING | Kd | 8.70 | IUPHAR | DRUG LABEL |
ID | Source |
---|---|
55KHL3P693 | UNII |
C4694273 | UMLSCUI |
CHEMBL3707328 | ChEMBL_ID |
DB14042 | DRUGBANK_ID |
D10936 | KEGG_DRUG |
10277 | INN_ID |
C000605816 | MESH_SUPPLEMENTAL_RECORD_UI |
8967 | IUPHAR_LIGAND_ID |
017757 | NDDF |
782371005 | SNOMEDCT_US |
782419003 | SNOMEDCT_US |
4037908 | VANDF |
4037909 | VANDF |
2058846 | RXNORM |
291703 | MMSL |
35092 | MMSL |
35093 | MMSL |
d08941 | MMSL |
C000628360 | MESH_SUPPLEMENTAL_RECORD_UI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
EMGALITY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-1436 | INJECTION, SOLUTION | 120 mg | SUBCUTANEOUS | BLA | 29 sections |
EMGALITY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-2377 | INJECTION, SOLUTION | 120 mg | SUBCUTANEOUS | BLA | 29 sections |
EMGALITY | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0002-3115 | INJECTION, SOLUTION | 100 mg | SUBCUTANEOUS | BLA | 29 sections |